Effect of Arg389Gly β1-adrenoreceptors Gene Polymorphism on the Parameters of Blood Pressure in Patients with Heart Failure and Systolic Left Ventricular Dysfunction

M.M. Udovychenko, Yu.S. Rudyk.

Abstract


Studies have been conducted to study the effects of Arg389Gly β1-adrenoceptor gene polymorphism on systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) in patients with chronic heart failure (HF), arterial hypertension (AH) in the background and without diabetes mellitus (DM) type 2, who received standard therapy for HF using bisoprolol for one year. At the beginning of our study it was shown that patients — carriers of Arg389Arg polymorphism type have higher SBP and DBP compared with Gly389 carriers regardless of DM type 2. When compared to groups similar results were obtained only in the group of patients without carbohydrate metabolism disorders.
More significant reduction in SBP and DBP was obtained in Arg389Arg and Arg389Gly gene B1AR polymorphism carriers against the background of standard therapy for HF using bisoprolol for 1 year in patients with HF and systolic dysfunction, regardless of diabetes type 2. Patients — homozygous Arg389 carriers reported the largest HR decrease in heart rate by 16.0 %, whereas in patients with Gly389Gly gene B1AR polymorphism heart rate decrease did not reach statistical significance.
Thus, the presence of Arg389 was associated with more significant decrease in SBP, DBP and HR at the background of standard therapy for HF using bisoprolol in patients with HF and systolic dysfunction, irrespective of DM type 2.


Keywords


chronic heart failure; β1-adrenoreceptor gene polymorphism; arterial hypertension; diabetes mellitus; beta-blockers

References


A polymorphism in the β1 adrenergic receptor is associated with resting heart rate / [Ranade K., Jorgenson E., Sheu W.-H. et al.] // Am. J. Hum. Genet. — 2002. — Vol. 70. — P. 935-942.

Elsner D. Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function / D. Elsner // Eur Heart J. — 1995. — Suppl. — P. 52–58.

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients / [Petersen M., Andersen J.T., Hjelvang B.R. et al.] // Br. J. Clin. Pharmacol. — 2011. — Vol. 71, № 4. — P. 556-565.

Brodde O.-E. Beta(1) and beta(2) adrenoreceptor polymorphism: Functional importance, impact on cardiovascular disease and drug response / O.-E. Brodde // Pharmacol. Ther. — 2008. — Vol. 117. — P. 1-29.

Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia / [Humma L.M., Puckett B.J., Richardson H.E. et al.] // Am. J. Cardiol. — 2001. — Vol. 88, № 9. — P. 1034-1037.

The CAREGENE study: polymorphisms of the β1 -adrenoceptor gene and aerobic power in coronary artery disease / [Defoor J., Martens K., Zieliska D. et al.] // Eur. Heart J. — 2006. — Vol. 27. — P. 808-816.

Arg389Gly beta1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo / [Xie H.G., Dishy V., Sofowora G. et al.] // Pharmacogenetics. — 2001. — Vol. 11, № 3. — P. 187-189.

Polymorphism of the β1-adrenergic receptors gene and hypertension / [Bengtsson K., Melander O., Orho-Melander M. et al.] // Circulation. — 2001. — Vol. 104. — P. 187-190.

Johson J. Pharmacogenetics of ß-Blockers / J. Johson // Pharmacotherapy. — 2007. — Vol. 27, № 6. — P. 874-887.

β1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol / [Johnson J.A., Zinech I., Puckett D.J. et al.] // Clin. Pharmacol. Ther. — 2003. — Vol. 74. — P. 44-52.




DOI: https://doi.org/10.22141/2224-1485.3.35.2014.82719

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru